Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Fractyl Health Q3 2026 Results: Net Loss of $14.2M, Loss Narrows

Fractyl Health reported a net loss of $30.5 million for the first nine months of 2026, a significant improvement from the $97.2 million loss in the prior year period, primarily driven by a $29.1 million gain from the change in fair value of warrant liabilities. The company implemented a strategic reprioritization in October 2026, including a workforce reduction, to extend its financial runway as cash and cash equivalents decreased to $31.5 million from $81.5 million at year-end 2025.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-14.2-45.6
EPS (diluted, $ a share)$-1.07$-8.46

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: GUTS. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Fractyl Health, Inc.: key numbers

Share price
$0.9654Close, Nov 17
Market cap
$12.8M
Shares outstanding
13.26MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Fractyl Health, Inc.

All →
4:06 PM ET 8-K
Financial Results

Fractyl Health Financial Results

Fractyl Health reported Q3 2026 financial results and announced a major strategic pivot to focus on its Revita program, including a 45% workforce reduction and the discontinuation of internal Rejuva development. The company reported positive six-month pivotal data from its REMAIN-1 trial and plans to submit an FDA De Novo marketing application in late Q4 2026.

Term
Q3 2026

“There are approximately 1 million Americans discontinuing GLP-1s each month, and these individuals are at high risk of weight and metabolic rebound. In this context, we believe the positive pivotal results from REMAIN-1 represent a defining moment for Fractyl. In the most rigorous stress test we could conceive, a single Revita procedure met its six-month co-primary endpoint with high statistical significance.”

Harith Rajagopalan, M.D., Ph.D., Co-Founder, President and Chief Executive Officer

“Armed with positive data, we have focused the Company around Revita’s post-GLP-1 weight maintenance opportunity. We expect the capital we have today to be sufficient to fund our planned De Novo submission and upcoming 12-month pivotal data and. Our goal is for Revita to potentially establish an entirely new therapeutic category of post-GLP-1 weight maintenance by aiming to reverse years of diet-induced damage to the gut.”

Harith Rajagopalan, M.D., Ph.D., Co-Founder, President and Chief Executive Officer
4:31 PM ET 8-K
Executive Compensation

Fractyl Health Executive Compensation

Fractyl Health appointed Michael Wartell as an independent Class III director, increasing the board size to ten members. Mr. Wartell will receive cash compensation of $40,000 per month and will not participate in the company's standard Non-Employee Director Compensation Policy. He brings over 35 years of experience in opportunistic credit and special situations to the board.

Counterparty
Michael Wartell
7:01 AM ET 8-K
Business Update

Fractyl Health Business Update

Fractyl Health is implementing a strategic reprioritization to focus on its Revita program, resulting in a 45% workforce reduction and the discontinuation of its Rejuva gene therapy program. The company expects to incur $2 million in severance charges while extending its cash runway into Q2 2027 and reducing quarterly cash burn by approximately 50%.

7:01 AM ET 8-K
Clinical Trial Data

Fractyl Health Clinical Trial Data

Fractyl Health announced positive topline six-month results from its REMAIN-1 Pivotal Cohort study evaluating the Revita DMR System for weight maintenance after GLP-1 therapy discontinuation. The study met its six-month co-primary endpoint with high statistical significance (p=0.0023), showing that Revita participants retained 80% of their weight loss compared to 67% for the sham group. The company plans to submit a De Novo marketing application to the FDA in late Q4 2026 based on these results.

6:30 AM ET 8-K
Reverse Stock Split

Fractyl Health Reverse Stock Split

Fractyl Health, Inc. has filed a Certificate of Amendment to effect a 1-for-12 reverse stock split of its outstanding common stock, effective October 2, 2026. The company's common stock will begin trading on a split-adjusted basis on The Nasdaq Global Market on October 5, 2026. The split was previously approved by stockholders at a special meeting on September 24, 2026.

4:16 PM ET 8-K
Reverse Stock Split

Fractyl Health Reverse Stock Split

Fractyl Health stockholders approved a series of alternate amendments to the company's Certificate of Incorporation to effect a reverse stock split. The Board of Directors has the discretion to select a ratio between 1-for-5 and 1-for-15. The measure was approved at a Special Meeting of Stockholders held on September 24, 2026.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.